Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam | Zendy

Ravina Kullar | Zendy; Flo﻿ri﻿an Wagenlehner | Zendy; Myra W. Popejoy | Zendy; Jianmin Long | Zendy; Brian Yu | Zendy; Ellie J. C. Goldstein | Zendy

Open Access

Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam

Author(s) -

Ravina Kullar,

Florian Wagenlehner,

Myra W. Popejoy,

Jianmin Long,

Brian Yu,

Ellie J. C. Goldstein

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw486

Subject(s) - meropenem , medicine , levofloxacin , tazobactam , population , urinary system , renal function , antibiotics , imipenem , antibiotic resistance , biology , environmental health , microbiology and biotechnology

For reasons not well understood, antibacterials can yield lower cure rates in renally impaired patients. We explored this subject for the novel antibacterial ceftolozane/tazobactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research